How to Audit Your Biosimilar Development and Comparability Process Before Inspectors Do

Context

Biosimilars have emerged as critical components of the biologics market, offering safe and effective alternatives to original biologics. The regulatory landscape governing biosimilar development and comparability is complex, governed by various agencies such as the FDA, EMA, and MHRA. Compliance with these regulations is essential not just for achieving a successful approval but also for ensuring ongoing market viability.

The primary focus of this article is to elucidate the key regulatory frameworks and guidelines surrounding biosimilar development and comparability. Understanding these elements is imperative for Regulatory Affairs (RA) professionals, as any oversight can lead to approval delays, increased scrutiny from regulatory bodies, and potential rejection of applications.

Legal/Regulatory Basis

In the landscape of biosimilars, the following regulations and guidelines are paramount:

• 21 CFR Part 601 – This regulation outlines the application process for biologics in the United States, including biosimilars.
• Regulation (EC) No 726/2004 – Establishes the procedures for the authorization and supervision of medicines, including biosimilars in the EU.
• MHRA Guidance: Guidelines provided by the UK’s Medicines and Healthcare products Regulatory Agency focus on the development and comparability of biological therapeutics.
• ICH Guidelines: The International Council for Harmonisation (ICH) has issued several pertinent guidelines like ICH Q5A and ICH Q6B that focus on quality aspects of biotechnological products.

These regulations collectively mandate comprehensive documentation, rigorous clinical trial data, and extensive characterization studies to establish biosimilarity. RA professionals should prioritize familiarization with these legal frameworks to understand agency expectations fully.

Documentation

Proper documentation is critical in ensuring compliance during the biosimilar development process. The key documentation requirements include:

• Quality Overall Summary (QOS): A comprehensive overview of the biosimilar’s quality attributes, which must comply with ICH Q6B standards.
• Comparability Exercise: Detailed evidence demonstrating that the biosimilar is highly similar to the reference product in terms of quality, safety, and efficacy.
• Clinical Data: Sufficient clinical studies must be documented to support the biosimilarity claim.
• Physicochemical and Biological Characterization: Extensive analytical studies to compare the biosimilar with its reference product.

When it comes to submissions, aligning the documentation with regulatory expectations can significantly streamline the review process. The FDA outlines in their guidance that sponsors must present data in a format that showcases clarity, robustness, and relevance to the biosimilar’s intended use.

Review/Approval Flow

Development Stage

The biosimilar development process can be divided into several key stages, each requiring careful navigation through regulatory expectations:

• Pre-Clinical Development: This involves initial comparability studies and should focus on physicochemical and biological characterization of the product.
• Clinical Development: Typically requires Phase I and II studies. The design should be justified to show adequate comparison with the reference product, particularly emphasizing endpoints that demonstrate safety and efficacy.
• Regulatory Submission: The compilation of all data into a Biologics License Application (BLA) in the US, or a Marketing Authorization Application (MAA) in the EU.

Regulatory Review Processes

During the regulatory review, agencies like the FDA and EMA will evaluate the submission based on:

• Quality data and comparability studies
• Clinical data demonstrating safety and efficacy
• Manufacturing processes, stability studies, and compliance to Good Manufacturing Practices (GMP)

Understanding the review timeline is critical. For instance, the FDA typically aims for a six-month review timeframe for priority applications and ten months for standard applications.

Common Deficiencies

Despite preparations, common deficiencies may arise leading to inquiries or delays. Among these, Regulatory Affairs teams should monitor:

• Insufficient Characterization Data: A frequent deficiency is inadequate demonstration of physiochemical and biological comparability. It is paramount to execute exhaustive characterization studies that cover the critical quality attributes.
• Inadequate Justification for Clinical Studies: RA professionals must articulate clear rationales for clinical study design. This includes justifying why certain endpoints were chosen and how they support the claim of biosimilarity.
• Manufacturing Issues: Any discrepancies in manufacturing practices between the biosimilar and the reference product can lead to concerns over product safety and efficacy.

RA-Specific Decision Points

When to File as a Variation vs. New Application

Understanding when to file a variation as opposed to a new application is crucial. A variation may be appropriate when:

• Minor changes in formulation or in the manufacturing process that do not significantly alter the quality, safety, or efficacy of the product.
• The change is aligned with an already approved version of the biosimilar, and updates are merely administrative.

On the contrary, a new application should be filed when:

• Substantial changes are made to the molecule that affect its characterization significantly.
• New indications, or dosing regimens are introduced that do not align with the existing product labeling.

How to Justify Bridging Data

Bridging studies are critical when there are changes to the manufacturing process. Regulatory bodies typically require justification for bridging data as follows:

• Demonstrate that the product originating from the new process is comparable to the clinical product used in previous studies.
• Employ analytical methods that are sensitive and specific for detecting differences in quality attributes.

RA professionals should integrate these bridging data justifications seamlessly into submission documentation to pre-empt concerns from regulatory review.

Practical Tips for Documentation and Responses to Agency Queries

Below are practical tips that RA professionals should keep in mind during the biosimilar development journey:

• Early Engagement with Regulatory Agencies: Involve regulatory authorities at early development stages to obtain feedback and alleviate uncertainties. Both the EMA and FDA recommend this proactive approach.
• Comprehensive Training for Teams: Regular training sessions should be conducted to ensure that CMC, QA, and RA departments consistently embody compliance standards and meet regulatory expectations.
• Internal Audits: Conduct internal audits prior to submission to identify any documentation shortfalls or evidence gaps that could trigger agency requests for additional information.
• Clear Communication: When responding to agency queries, ensure communications are clear, factual, and supported by data. Avoid jargon unless necessary.

Conclusion

Successfully navigating the intricate landscape of biosimilar development and comparability requires a comprehensive understanding of the legal frameworks, robust documentation practices, and an anticipation of common deficiencies. By conducting internal audits, RA teams can preemptively address potential regulatory concerns and ensure inspection readiness.

Through strategic planning and rigorous adherence to guidelines set forth by agencies such as the FDA, EMA, and MHRA, organizations can enhance their submission strategy, mitigate approval delays, and support high-quality patient care.